CraniUS has been awarded a competitive $1 million grant from the state of Maryland to advance its skull-embedded neurotechnology research.

CraniUS获得了马里兰州100万美元的竞争性拨款，以推进其颅骨嵌入神经技术研究。

The grant is part of Gov. Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program and represents the first funding awarded as part of the initiative. The money will help CraniUS expand its research capabilities, accelerate product development into human studies, and enhance its contributions to Maryland’s innovation ecosystem..

该赠款是州长韦斯·摩尔（WesMoore）的“构建我们未来的创新基础设施”试点计划的一部分，是该计划的第一笔资金。这笔资金将帮助CraniUS扩大其研究能力，加速产品开发进入人体研究，并增强其对马里兰州创新生态系统的贡献。。

Moore last year officially launched the Build Our Future program—a $9 million initiative designed to support transformative projects across Maryland’s strategic industry sectors. The program provides matching grants of up to $2 million to projects that demonstrate a substantial impact on growth and innovation within the state..

摩尔（Moore）去年正式启动了“构建我们的未来”计划，该计划耗资900万美元，旨在支持马里兰州战略性产业部门的转型项目。该计划为那些对该州的增长和创新产生重大影响的项目提供了高达200万美元的配套赠款。。

CraniUS’s work in skull-embedded neurotechnology aims to revolutionize treatments for neurological disorders by pioneering a new frontier: the brain-medicine interface (BMI), creating an expansive new platform in neurological medicines that can be delivered safely and directly to the brain to treat multiple diseases.

CraniUS在颅骨嵌入神经技术方面的工作旨在通过开创一个新的前沿：脑医学界面（BMI）来彻底改变神经疾病的治疗方法，为神经药物创造一个广阔的新平台，可以安全直接地输送到大脑以治疗多种疾病。

Its patented flagship device, the NeuroPASS, is being specifically developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective..

其获得专利的旗舰设备NeuroPASS正在专门开发中，以绕过血脑屏障带来的挑战，血脑屏障使传统的脑部疾病治疗无效。。

'We are thrilled and grateful to receive this support from the State of Maryland,' CraniUS CEO Mike Maglin said. 'This grant is not just a recognition of our groundbreaking work, but a testament to the state’s commitment to fostering innovation and supporting high-impact projects. With this funding, we are poised to make significant strides in our mission to develop life-changing neurotechnology solutions.'.

CraniUS首席执行官迈克·马格林（MikeMaglin）说，我们很高兴并感谢马里兰州的支持这笔赠款不仅是对我们开创性工作的认可，也是对国家致力于促进创新和支持高影响力项目的证明。有了这笔资金，我们准备在开发改变生活的神经技术解决方案的使命中取得重大进展。”。

CraniUS was founded May 2021 in Baltimore, Md., as a byproduct of the emerging neuroplastic and reconstructive surgery field through the vision, insight, and work of Dr. Chad Gordon. CraniUS has raised more than $24 million to date, been issued seven patents, and is currently in the midst of a Series B fundraising round..

CraniUS于2021年5月在马里兰州巴尔的摩成立，是通过Chad Gordon博士的远见，洞察力和工作，新兴神经塑性和重建手术领域的副产品。到目前为止，CraniUS已经筹集了2400多万美元，获得了7项专利，目前正在进行B系列融资。。

CraniUS's NeuroPASS device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies.

CraniUS的NeuroPASS设备目前处于临床前开发阶段，尚未上市。它正在走向临床研究。